<DOC>
	<DOCNO>NCT00736333</DOCNO>
	<brief_summary>This study evaluate safety tolerability Caelyx use treatment metastatic breast cancer ( MBC ) , focus infusion reaction palmar-plantar erythrodysesthesia ( PPE ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx ( Study P04878 ) ( COMPLETED )</brief_title>
	<detailed_description>Patients select investigator accord clinical routine</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients metastatic breast cancer History hypersensitivity Caelyx component Women pregnant breastfeeding Patients severe myelosuppression</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>